{
  "company_name": "Cheplapharm",
  "legal_entity": "Cheplapharm SE",
  "operating_entity": "CHEPLAPHARM Arzneimittel GmbH",
  "sector": "Healthcare - Specialty Pharma",
  "geography": "Germany",
  "last_updated": "2026-01-21",
  "data_source": "Debtwire",

  "ratings": {
    "moodys": {"rating": "B3", "outlook": null},
    "sp": {"rating": "B", "outlook": null}
  },

  "overview": {
    "business_description": "Specialty pharma platform acquiring and managing established pharmaceutical brands globally. Serial acquirer of off-patent/mature drugs from big pharma companies including Eli Lilly, Bristol-Myers, AstraZeneca, Takeda, Sanofi, and others.",
    "business_positives": [
      "Diversified portfolio of established pharma brands",
      "Recurring cash flows from mature, off-patent drugs",
      "Proven M&A execution - multiple successful acquisitions",
      "Bonds trading near/above par - market comfortable with credit",
      "No near-term maturities until Jan 2028",
      "Strong relationship with big pharma for deal flow"
    ],
    "fatal_flaw": "EBITDA declined 13.9% YoY in 1H25 to EUR 337.6m. Distress score of 28 is elevated. Acquisition-dependent model requires constant execution. Private company = limited transparency.",
    "ownership": "Private - Atlantic Park Strategic Capital (minority stake acquired Oct 2022 at $545m)",
    "recent_news": "1H25 EBITDA declines 13.9% YoY to EUR 337.6m. Issued EUR 750m Sr Secd Notes at 7.125% (Jun 2025). Pending acquisition of Eli Lilly's Gemzar worldwide rights."
  },

  "quick_assessment": {
    "total_debt": 4835,
    "cash_on_hand": null,
    "revolver_available": 422,
    "revolver_drawn": 273,
    "debt_due_one_year": 0,
    "cffo": null,
    "interest_expense": null,
    "ebitda_1h25_annualized": 675
  },

  "key_ratios": {
    "debt_to_ebitda": null,
    "net_debt_to_ebitda": null,
    "ebitda_minus_capex_to_interest": null,
    "fcf_to_debt": null
  },

  "debt_capitalization": [
    {
      "instrument": "EUR 695m Revolving Credit",
      "amount": 273,
      "maturity": "Apr 2028",
      "coupon": null,
      "price": null,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 1480m Term Loan B First Lien",
      "amount": 1682,
      "maturity": "Feb 2029",
      "coupon": "E+400bps",
      "price": 100.40,
      "ytw": null,
      "stw": null,
      "rating": null,
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 325m Sr Secd Notes",
      "amount": 348,
      "maturity": "May 2030",
      "coupon": "E+475bps",
      "price": 100.04,
      "ytw": 7.05,
      "stw": null,
      "rating": "B3/B",
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 425m Sr Secd Notes",
      "amount": 455,
      "maturity": "May 2030",
      "coupon": "7.50%",
      "price": 103.32,
      "ytw": 6.60,
      "stw": null,
      "rating": "B3/B",
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 300m Sr Secd Notes",
      "amount": 321,
      "maturity": "May 2030",
      "coupon": "7.50%",
      "price": 103.32,
      "ytw": 6.60,
      "stw": null,
      "rating": "B3/B",
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 750m Sr Secd Notes (Jun 2025)",
      "amount": 865,
      "maturity": "Jun 2031",
      "coupon": "7.125%",
      "price": 101.80,
      "ytw": 6.72,
      "stw": null,
      "rating": "B3",
      "seniority": "Senior Secured"
    },
    {
      "instrument": "EUR 575m Notes (Unsecured)",
      "amount": 675,
      "maturity": "Jan 2028",
      "coupon": "4.375%",
      "price": 99.63,
      "ytw": 4.57,
      "stw": null,
      "rating": "B3/B",
      "seniority": "Senior Unsecured"
    },
    {
      "instrument": "USD 500m Notes (Unsecured)",
      "amount": 215,
      "maturity": "Jan 2028",
      "coupon": "5.50%",
      "price": 98.81,
      "ytw": 6.14,
      "stw": null,
      "rating": "B",
      "seniority": "Senior Unsecured"
    }
  ],

  "maturity_schedule": {
    "year_1": 0,
    "year_2": 0,
    "year_3": 1163,
    "year_4": 1682,
    "year_5": 1124,
    "thereafter": 865
  },

  "maturity_detail": {
    "2028": "EUR 575m + USD 500m unsecured notes (~$890m) + RCF (~$273m)",
    "2029": "EUR 1480m TLB (~$1.68bn)",
    "2030": "EUR 1050m secured notes (~$1.12bn)",
    "2031": "EUR 750m secured notes (~$865m)"
  },

  "acquisition_history": [
    {"date": "Oct 2024", "target": "Eli Lilly - Gemzar worldwide rights", "status": "Pending"},
    {"date": "Nov 2023", "target": "Chugai - Xeloda Japan", "value": null},
    {"date": "Apr 2023", "target": "Eli Lilly - Zyprexa", "value": 1400},
    {"date": "Mar 2022", "target": "Bristol-Myers - Oncology drugs (Hydrea, Paraplatin, Taxol)", "value": null},
    {"date": "Jun 2021", "target": "Astellas - Infectious disease drugs", "value": 115},
    {"date": "Jan 2021", "target": "AstraZeneca - Atacand", "value": 400},
    {"date": "Sep 2020", "target": "Takeda - Non-core assets Europe/Canada", "value": 562},
    {"date": "Aug 2020", "target": "Leo Pharma - One-Alpha, Locoid, Pimafucin, Zineryt", "value": 358}
  ],

  "credit_opinion": {
    "recommendation": "NEUTRAL",
    "summary": "Cheplapharm is a B3/B rated specialty pharma with an elevated distress score of 28. The 1H25 EBITDA decline of 13.9% YoY is concerning and warrants monitoring. However, bonds are trading near/above par (secured at 100-103, unsecured at 98-99) suggesting market is comfortable. The acquisition-dependent model requires constant execution. No near-term maturities until Jan 2028 (~$890m unsecured) provides some runway. Total debt of ~$4.8bn is substantial.",
    "key_risks": [
      "EBITDA declining 13.9% YoY in 1H25 - trend reversal needed",
      "Elevated distress score of 28",
      "Acquisition-dependent model - execution risk on each deal",
      "Private company with limited financial transparency",
      "Large debt stack ($4.8bn) relative to EBITDA",
      "Jan 2028 maturity wall (~$890m unsecured notes) approaching",
      "Integration risk from multiple concurrent acquisitions"
    ],
    "key_catalysts": [
      "EBITDA stabilization or return to growth",
      "Successful Gemzar acquisition closing",
      "Proactive refinancing of Jan 2028 unsecured notes",
      "Additional accretive M&A at attractive valuations",
      "Potential rating upgrade if leverage improves"
    ]
  },

  "distress_indicators": {
    "debtwire_distress_score": 28,
    "lifecycle_status": "Performing credit",
    "trading_signals": "Secured bonds at 100-103 (near/above par), unsecured at 98-99 (near par). TLB at 100.40. Market pricing as stable B credit despite elevated distress score."
  }
}
